Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
Abstract Heterogeneity has been demonstrated to be a predictor of treatment failure and drug resistance. Our study aimed to investigate imaging parameters, including tumor heterogeneity, as prognostic factors of response to 500 mg fulvestrant using 18F-FDG PET/CT. Twenty-seven estrogen receptor (HR)...
Guardado en:
Autores principales: | Yannan Zhao, Cheng Liu, Yingjian Zhang, Chengcheng Gong, Yi Li, Yizhao Xie, Bingrui Wu, Zhongyi Yang, Biyun Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/53499fd6cb6449139ee0ba36d9607cf7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
FDG-PET/CT in predicting aggressiveness of rectal cancer
por: Iman Sherif Ahmed, et al.
Publicado: (2021) -
Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
por: Etienne Lavallee, et al.
Publicado: (2021) -
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida M, et al.
Publicado: (2020) -
Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer
por: Cenzhu Wang, et al.
Publicado: (2021) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021)